A Systematic Review of Direct Cardiovascular Event Costs: An International Perspective

Steve Ryder (), Kathleen Fox, Pratik Rane, Nigel Armstrong, Ching-Yun Wei, Sohan Deshpande, Lisa Stirk, Yi Qian and Jos Kleijnen
Additional contact information
Steve Ryder: Kleijnen Systematic Reviews Ltd
Kathleen Fox: Strategic Healthcare Solutions LLC
Pratik Rane: Amgen Inc
Nigel Armstrong: Kleijnen Systematic Reviews Ltd
Ching-Yun Wei: Kleijnen Systematic Reviews Ltd
Sohan Deshpande: Kleijnen Systematic Reviews Ltd
Lisa Stirk: Kleijnen Systematic Reviews Ltd
Yi Qian: Amgen Inc
Jos Kleijnen: Maastricht University

PharmacoEconomics, 2019, vol. 37, issue 7, No 4, 895-919

Abstract: Abstract Introduction There is a lack of comprehensive cost information for cardiovascular events since 2013. Objective A systematic review on the contemporary cost of cardiovascular events was therefore undertaken. Methods Methods complied with those recommended by the Cochrane Collaboration and the Centre for Reviews and Dissemination. Studies were unrestricted by language, were from 2013 to 23 December 2017, and included cost-of-illness data in adults with the following cardiovascular conditions: myocardial infarction (MI), stroke, transient ischaemic attack (TIA), heart failure (HF), unstable angina (UA), coronary artery bypass graft (CABG), percutaneous coronary intervention (PCI), or peripheral artery disease (PAD). Seven electronic databases were searched, namely Embase (Ovid), MEDLINE (Ovid), MEDLINE In-Process Citations and Daily Update (Ovid), NHS Economic Evaluation Database (NHS EED), Health Technology Assessment (HTA) database, Cochrane Central Register of Controlled Trials (CENTRAL), and PubMed. The included studies reported data from a variety of years (sometimes prior to 2013), so costs were inflated and converted to $US, year 2018 values, for standardization. Results After de-duplication, 29,945 titles and abstracts and then 403 full papers were screened; 82 studies (88 papers) were extracted. Year 1 average cost ranges were as follows: MI ($11,970 in Sweden to $61,864 in the USA), stroke ($10,162 in Spain to $46,162 in the USA), TIA ($6049 in Sweden to $25,306 in the USA), HF ($4456 in China to $49,427 in the USA), UA ($11,237 in Sweden to $31,860 in the USA), PCI ($17,923 in Italy to $45,533 in the USA), CABG ($17,972 in the UK to $76,279 in the USA). One Swedish study reported PAD costs in a format convertible to $US, 2018 values, with a mean annual cost of $15,565. Conclusions There was considerable unexplained variation in contemporary costs for all major cardiovascular events. One emerging theme was that average costs in the USA were considerably higher than anywhere else.

Date: 2019
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
http://link.springer.com/10.1007/s40273-019-00795-4 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharme:v:37:y:2019:i:7:d:10.1007_s40273-019-00795-4

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40273

DOI: 10.1007/s40273-019-00795-4

Access Statistics for this article

PharmacoEconomics is currently edited by Timothy Wrightson and Christopher I. Carswell

More articles in PharmacoEconomics from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().